Tobacco 21 FAQ

Letter of support

Tobacco 21 Draft Ordinance

Puerto Rico Relief - Volunteer FAQs

San Antonio For Puerto Rico

Physician Volunteer Request - FAQ’s

Puerto Rico is trying to organize efforts to have physicians volunteer to travel to Puerto Rico to help patients impacted by Hurricane Maria. A flyer has been prepared with information about the conditions of the volunteer service. Following are some frequently asked questions about the volunteer conditions.

1.       Who in San Antonio is coordinating this effort to volunteer to serve in Puerto Rico?

Carmelo Otero, MD: Cell phone – 210-383-1828; Fax – 210-615-6626; Email - drotero@cmics-sa.com

2.       Will I be paid as a physician to volunteer in Puerto Rico?

No, this is a volunteer effort. No physicians will be paid for their services.

3.       How will volunteers get to Puerto Rico, where will they stay and who will pay for the costs?

Volunteer physicians must book commercial airlines to travel to and from Puerto Rico. The costs of travel, lodging, food and other expenses are the responsibility of the volunteer physicians. However, the governor will ensure lodging will be available for volunteers.

4.       Will volunteers need a visa to be able to enter Puerto Rico?

The governor has ensured that all volunteer physicians with a valid medical license, under governor’s order #OE-2017-58, will be able to practice in Puerto Rico.

5.       Does physician medical mal practice insurance cover services provided in Puerto Rico?

Each physician should check with their medical malpractice insurance provider as to their own coverage.

6.       Where in Puerto Rico will volunteers be working?

The government in Puerto Rico will assign areas most in need at the time.

7.       Will the medical supplies be provided?

In some cases, yes, and in others no. Donations are being sought to cover the cost of supplies. A list of needed supplies can be provided.

8.       Are donations being sought? Where do I send the check?

Monetary donations may be sent to (please put Doctors 4 Puerto Rico on the Memo line on the check):

The Puerto Rico Heritage Society, Attn: Doctors 4 Puerto Rico

225 E Sonterra Blvd, Suite 201

San Antonio, TX  78258

San Antonio for Puerto Rico

Input Needed for Development of Designated Doctor Plan-Based Audit

MedDrop SA - Sept. 16

BCMS Golden Aesculapius Award Nominations

GOLDEN AESCULAPIUS AWARDS

The Bexar County Medical Society periodically honors chosen physicians who have given much to the medical community in the form of lifetime service to organized medicine, or have made other significant contributions to the practice of medicine. Dr. Jayesh Shaw has asked that each of you consider and recommend BCMS physicians whom you believe should be considered for one of these awards. Obviously, we can’t give awards to everyone, but we would like to hear from you on who you think should be considered and recognized for these awards and why. Please send your recommendations to the attention of Steve Fitzer (steve.fitzer@bcms.org) and Jayesh Shah, MD (jshahaapi@gmail.com). Golden Aesculapius Award In 1980, the Bexar County Medical Society established the Aesculapius Award as our highest honor recognizing a lifetime of distinguished service by a BCMS member to our patients and our profession. This award is not given annually but only upon the occasion of nomination and confirmation of distinguished service. Those who have received the award are: Alvin O. Severance, M.D.       1980 John M. Smith, Jr., M.D.         1984 John J. Hinchey, M.D.             1985 Charles A. Hulse, M.D.           1996 Merle W. Delmer, M.D.          1998 Al Sanders, M.D.                     2006 Robert N. Jones, M.D.             2009 Jose M. Benavides, M.D.         2010 Harmon W. Kelley, M.D.        2011 Antonio Cavazos, Jr., M.D.     2013 Distinguished Service Award At the January 13, 2009, meeting of the BCMS Past Presidents Advisory Council, the BCMS Distinguished Service Award was established. The first recipient of the BCMS Distinguished Service Award will be William H. “Bill” Hinchey, MD. Award presented at the Installation of Officers.                                          Date presented William H. “Bill” Hinchey, MD     2009 George “Rick” Evans              2010 Charles Rockwood, MD          2010 Marion Primomo                     2011

BCMS Leadership Nominations

LEADERSHIP NOMINATIONS CALL FOR BCMS LEADERSHIP NOMINATIONS It is time to nominate physicians to serve in leadership positions of the Bexar County Medical Society in 2017. Nomination Deadline - 5 p.m., JULY 13, 2016. In accordance with Chapter 8, Section 8.31, of the Bylaws of the Bexar County Medical Society, "Each member shall have the opportunity to correspond in writing for the purpose of submitting nominations to the Nominating Committee. Nominations shall . . . reflect nominee’s character, integrity, attributes, and qualifications for the position." The BCMS is calling for written nominations for the following positions with terms beginning in 2017: □     President-elect – assists President; is ex-officio member of all boards and committees; and becomes acquainted with all matters pertaining to work and affairs of the Society to properly prepare for office of President, which office is automatically assumed at expiration of one-year term as President-elect. President-elect shall have been a member of BCMS for minimum of five years. □     Vice President – assists President; presides in President’s absence; and, on President’s death, resignation or removal, succeeds to presidency. Term of office shall be one year; tenure of office shall not exceed one term – shall have been a member of BCMS for minimum of five years. □   Secretary – makes certain adequate records of meetings of Society and Board of Directors are maintained; is responsible for such records and reports as may be required by Board of Directors or Bylaws of Society or TMA. Term of office shall be one year; tenure of office shall not exceed two terms – shall have been a member of BCMS for minimum of two years. □   Treasurer – makes regular reports to Board of Directors on financial status of Society. Term of office shall be one year; tenure of office shall not exceed two terms – shall have been a member of BCMS for minimum of two years.  □   Director – 3 at-large positions – establishes and implements policies of Society; acts upon applications for membership upon recommendation from Board of Censors; conducts disciplinary hearings as prescribed by Hearings Procedures Manual; is responsible for long-range planning; decides all questions not specifically delegated to other authorities. Meetings are held a minimum of six times per year – term of office shall be three years; tenure of office shall not exceed two terms. □   Member Board of Censors – 2 positions – supervises medical ethics of membership and counsels individual members where circumstances warrant; examines applicants for membership; investigates suspected violations of code of conduct and prefers charges when indicated; receives investigative charges of unethical conduct made against Society members by another member; and, upon request, reviews findings of Board of Mediations and makes proper disposition of each case. Meets monthly – term of office shall be three years – shall have been a member of BCMS for minimum of ten years. □   Member Board of Mediations – 5 positions – receives, investigates, and mediates complaints from patients or insurance companies brought against member of Society; hears matters of unprofessional conduct, violations of principles of medical ethics or any other matter involving patient/physician relationship; hears and/or reviews insurance complaints; investigates and supervises ethical deportment of membership and receives complaints from general public. Meets monthly – term of office shall be three years – shall have been a member of BCMS for minimum of ten years. □   Delegate/Alternate Delegate to TMA – 30 positions – studies needs and desires of medical profession in Bexar County in its relation to state and national associations to effectively and intelligently represent the membership of Society in TMA House of Delegates (two meetings a year). Meets at least four times a year in San Antonio – term of office shall be two years. □   Member Nominating Committee – 2 positions – studies the challenges and leadership requirements of the organization. The committee will commence its functions from January 1 of each year. Meetings of the committee shall be held at least two times a year and as often as necessary – term of office is one year. Members of the committee will not seek an elected position (other than Delegate or Alternate Delegate) in the Society.          Please seriously consider getting involved with the leadership of BCMS; don’t leave it to someone else to watch out for the practice of medicine. Below, please indicate which position you are interested in running for or for which you are nominating a colleague. If you are nominating yourself or someone else please indicate below. Thank you! Your Name:                                                      Nominating Self:                    Phone:                                   Position:                                                                                                      Name of Person You are Nominating:                                                            Phone:                                   Nominations must be submitted in writing via email, fax, or mail. CVs will be required from all nominees. Click here for an online nomination form. Or Mail to: Bexar County Medical Society Attn: Nominating Committee P.O. Box 781145, San Antonio, TX 78278 or by email to bcms@bcms.org or fax to (210) 301-2150 Nomination Deadline - 5 p.m., JULY 13, 2016.

UIWSOM Interviewer Participant Form

City Health Advisory

TMA Legislative Wins

TMA 84th Lege Session Summary

BCMS Building Space for Lease

TAC Chapter 134

CHAPTER 134:  BENEFITS – GUIDELINES FOR MEDICAL SERVICES, CHARGES, AND PAYMENTS

Title 28 Texas Administrative Code (TAC) § 134.500, § 134.530 and § 134.540

 

§134.500. Definitions.

(a)    The following words and terms, when used in this subchapter, have the following meanings, unless the context clearly indicates otherwise:

(1) Brand name drug--A drug marketed under a proprietary, trademark-protected name.

(2) Certified workers' compensation health care network (certified network)--An organization that is certified in accordance with Insurance Code Chapter 1305 and department rules.

(3) Closed formulary--All available Food and Drug Administration (FDA) approved prescription and nonprescription drugs prescribed and dispensed for outpatient use, but excludes:

(A) drugs identified with a status of "N" in the current edition of the Official Disability Guidelines Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;

(B) any prescription drug created through compounding [any compound that contains a drug identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates]; and

(C) any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

(4) Compounding--As defined under Occupations Code §551.003(9), the preparation, mixing, assembling, packaging, or labeling of a drug or device:

(A) as the result of a practitioner's prescription drug order based on the practitioner-patient-pharmacist relationship in the course of professional practice;

(B) for administration to a patient by a practitioner as the result of a practitioner's initiative based on the practitioner-patient-pharmacist relationship in the course of professional practice;

(C) in anticipation of a prescription drug order based on a routine, regularly observed prescribing pattern; or

(D) for or as an incident to research, teaching, or chemical analysis and not for selling or dispensing, except as allowed under Occupations Code §562.154 or Occupations Code Chapter 563.

(5) Generic--See generically equivalent in definition of paragraph (6) of this section.

(6) Generically equivalent--As defined under Occupations Code §562.001, a drug that, when compared to the prescribed drug, is:

(A) pharmaceutically equivalent--Drug products that have identical amounts of the same active chemical ingredients in the same dosage form and that meet the identical compendia or other applicable standards of strength, quality, and purity according to the United States Pharmacopoeia or another nationally recognized compendium; and

(B) therapeutically equivalent--Pharmaceutically equivalent drug products that, if administered in the same amounts, will provide the same therapeutic effect, identical in duration and intensity.

(7) Medical emergency--The sudden onset of a medical condition manifested by acute symptoms of sufficient severity, including severe pain that in the absence of immediate medical attention could reasonably be expected to result in:

(A) placing the patient's health or bodily functions in serious jeopardy; or

(B) serious dysfunction of any body organ or part.

(8) Nonprescription drug or over-the-counter medication--A non-narcotic drug that may be sold without a prescription and that is labeled and packaged in compliance with state or federal law.

(9) Open formulary--Includes all available Food and Drug Administration (FDA) approved prescription and nonprescription drugs prescribed and dispensed for outpatient use, but does not include drugs that lack FDA approval, or non-drug items.

(10) Prescribing doctor--A physician or dentist who prescribes prescription drugs or over the counter medications in accordance with the physician's or dentist's license and state and federal laws and rules. For purposes of this chapter, prescribing doctor includes an advanced practice nurse or physician assistant to whom a physician has delegated the authority to carry out or sign prescription drug orders, under Occupations Code Chapter 157, who prescribes prescription drugs or over the counter medication under the physician's supervision and in accordance with the health care practitioner's license and state and federal laws and rules.

(11) Prescription--An order for a prescription or nonprescription drug to be dispensed.

(12) Prescription drug--

(A) A substance for which federal or state law requires a prescription before the substance may be legally dispensed to the public;

(B) A drug that under federal law is required, before being dispensed or delivered, to be labeled with the statement: "Caution: federal law prohibits dispensing without prescription;" "Rx only;" or another legend that complies with federal law; or

(C) A drug that is required by federal or state statute or regulation to be dispensed on prescription or that is restricted to use by a prescribing doctor only.

(13) Statement of medical necessity--A written statement from the prescribing doctor to establish the need for treatments or services, or prescriptions, including the need for a brand name drug where applicable. A statement of medical necessity shall include:

(A) the injured employee's full name;

(B) date of injury;

(C) social security number;

(D) diagnosis code(s);

(E) whether the drug has previously been prescribed and dispensed, if known, and whether the inability to obtain the drug poses an unreasonable risk of a medical emergency; and

(F) how the prescription treats the diagnosis, promotes recovery, or enhances the ability of the injured employee to return to or retain employment.

(14) Substitution--As defined under Occupations Code §551.003(41), the dispensing of a drug or a brand of drug other than the drug or brand of drug ordered or prescribed.

(b)     This section will become effective for all drugs that are prescribed and dispensed for outpatient use on or after MM/DD/YY (intended to be a date certain approximately sixty days after the rule amendment is finally adopted).

§134.530. Requirements for Use of the Closed Formulary for Claims Not Subject to Certified Networks.

(a) Applicability. The closed formulary applies to all drugs that are prescribed and dispensed for outpatient use for claims not subject to a certified network on or after September 1, 2011 when the date of injury occurred on or after September 1, 2011.

(b) Preauthorization for claims subject to the Division's closed formulary.

(1) Preauthorization is only required for:

(A) drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;

(B) any prescription drug created through compounding [any compound that contains a drug identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates]; and

(C) any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

(2) When §134.600(p)(12) of this title (relating to Preauthorization, Concurrent Review, and Voluntary Certification of Health Care) conflicts with this section, this section prevails.

(c) Preauthorization of intrathecal drug delivery systems.

(1) An intrathecal drug delivery system requires preauthorization in accordance with §134.600 of this title and the preauthorization request must include the prescribing doctor's drug regime plan of care, and the anticipated dosage or range of dosages for the administration of pain medication.

(2) Refills of an intrathecal drug delivery system with drugs excluded from the closed formulary, which are billed using Healthcare Common Procedure Coding System (HCPCS) Level II J codes, and submitted on a CMS-1500 or UB-04 billing form, require preauthorization on an annual basis. Preauthorization for these refills is also required whenever:

(A) the medications, dosage or range of dosages, or the drug regime proposed by the prescribing doctor differs from the medications, dosage or range of dosages, or drug regime previously preauthorized by that prescribing doctor; or

(B) there is a change in prescribing doctor.

(d) Treatment guidelines. Except as provided by this subsection, the prescribing of drugs shall be in accordance with §137.100 of this title (relating to Treatment Guidelines), the division's adopted treatment guidelines.

(1) Prescription and nonprescription drugs included in the division's closed formulary and recommended by the division's adopted treatment guidelines may be prescribed and dispensed without preauthorization.

(2) Prescription and nonprescription drugs included in the division's closed formulary that exceed or are not addressed by the division's adopted treatment guidelines may be prescribed and dispensed without preauthorization.

(3) Drugs included in the closed formulary that are prescribed and dispensed without preauthorization are subject to retrospective review of medical necessity and reasonableness of health care by the insurance carrier in accordance with subsection (g) of this section.

(e) Appeals process for drugs excluded from the closed formulary.

(1) For situations in which the prescribing doctor determines and documents that a drug excluded from the closed formulary is necessary to treat an injured employee's compensable injury and has prescribed the drug, the prescribing doctor, other requestor, or injured employee must request approval of the drug by requesting preauthorization, including reconsideration, in accordance with §134.600 of this title and applicable provisions of Chapter 19 of this title (relating to Agents' Licensing).

(2) If preauthorization is being requested by an injured employee or a requestor other than the prescribing doctor, and the injured employee or other requestor requests a statement of medical necessity, the prescribing doctor shall provide a statement of medical necessity to facilitate the preauthorization submission as set forth in §134.502 of this title (relating to Pharmaceutical Services).

(3) If preauthorization for a drug excluded from the closed formulary is denied, the requestor may submit a request for medical dispute resolution in accordance with §133.308 of this title (relating to MDR by Independent Review Organizations).

(4) In the event of an unreasonable risk of a medical emergency, an interlocutory order may be obtained in accordance with §133.306 of this title (relating to Interlocutory Orders for Medical Benefits) or §134.550 of this title (relating to Medical Interlocutory Order).

(f) Initial pharmaceutical coverage.

(1) Drugs included in the closed formulary which are prescribed for initial pharmaceutical coverage, in accordance with Labor Code §413.0141, may be dispensed without preauthorization and are not subject to retrospective review of medical necessity.

(2) Drugs excluded from the closed formulary which are prescribed for initial pharmaceutical coverage, in accordance with Labor Code §413.0141, may be dispensed without preauthorization, except as referenced in subsection (b)(1)(C) of this section, and are subject to retrospective review of medical necessity.

(g) Retrospective review. Except as provided in subsection (f)(1) of this section, drugs that do not require preauthorization are subject to retrospective review for medical necessity in accordance with §133.230 of this title (relating to Insurance Carrier Audit of a Medical Bill) and §133.240 of this title (relating to Medical Payments and Denials), and applicable provisions of Chapter 19 of this title.

(1) Health care, including a prescription for a drug, provided in accordance with §137.100 of this title is presumed reasonable as specified in Labor Code §413.017, and is also presumed to be health care reasonably required as defined by Labor Code §401.011(22-a).

(2) In order for an insurance carrier to deny payment subject to a retrospective review for pharmaceutical services that are recommended by the division's adopted treatment guidelines, §137.100 of this title, the denial must be supported by documentation of evidence-based medicine that outweighs the presumption of reasonableness established under Labor Code §413.017.

(3) A prescribing doctor who prescribes pharmaceutical services that exceed, are not recommended, or are not addressed by §137.100 of this title, is required to provide documentation upon request in accordance with §134.500(13) of this title (relating to Definitions) and §134.502(e) and (f) of this title.

(h)  This section will become effective for all drugs that are prescribed and dispensed for outpatient use on or after MM/DD/YY (intended to be a date certain approximately sixty days after the rule amendment is finally adopted).

§134.540. Requirements for Use of the Closed Formulary for Claims Subject to Certified Networks.

(a) Applicability. The closed formulary applies to all drugs that are prescribed and dispensed for outpatient use for claims subject to a certified network on or after September 1, 2011 when the date of injury occurred on or after September 1, 2011.

(b) Preauthorization for claims subject to the Division's closed formulary. Preauthorization is only required for:

(1) drugs identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates;

(2) any prescription drug created through compounding [any compound that contains a drug identified with a status of "N" in the current edition of the ODG Treatment in Workers' Comp (ODG) / Appendix A, ODG Workers' Compensation Drug Formulary, and any updates]; and

(3) any investigational or experimental drug for which there is early, developing scientific or clinical evidence demonstrating the potential efficacy of the treatment, but which is not yet broadly accepted as the prevailing standard of care as defined in Labor Code §413.014(a).

(c) Preauthorization of intrathecal drug delivery systems.

(1) An intrathecal drug delivery system requires preauthorization in accordance with the certified network's treatment guidelines and preauthorization requirements pursuant to Insurance Code Chapter 1305 and Chapter 10 of this title (relating to Workers' Compensation Health Care Networks).

(2) Refills of an intrathecal drug delivery system with drugs excluded from the closed formulary, which are billed using Healthcare Common Procedure Coding System (HCPCS) Level II J codes, and submitted on a CMS-1500 or UB-04 billing form, require preauthorization on an annual basis. Preauthorization for these refills is also required whenever:

(A) the medications, dosage or range of dosages, or the drug regime proposed by the prescribing doctor differs from the medications dosage or range of dosages, or drug regime previously preauthorized by that prescribing doctor; or

(B) there is a change prescribing doctor.

(d) Treatment guidelines. The prescribing of drugs shall be in accordance with the certified network's treatment guidelines and preauthorization requirements pursuant to Insurance Code Chapter 1305 and Chapter 10 of this title. Drugs included in the closed formulary that are prescribed and dispensed without preauthorization are subject to retrospective review of medical necessity and reasonableness of health care by the insurance carrier in accordance with subsection (f) of this section.

(e) Appeals process for drugs excluded from the closed formulary.

(1) For situations in which the prescribing doctor determines and documents that a drug excluded from the closed formulary is necessary to treat an injured employee's compensable injury and has prescribed the drug, the prescribing doctor, other requestor, or injured employee must request approval of the drug in a specific instance by requesting preauthorization in accordance with the certified network's preauthorization process established pursuant to Chapter 10, Subchapter F of this title (relating to Utilization Review and Retrospective Review) and applicable provisions of Chapter 19 of this title (relating to Agents' Licensing).

(2) If preauthorization is pursued by an injured employee or requestor other than the prescribing doctor, and the injured employee or other requestor requests a statement of medical necessity, the prescribing doctor shall provide a statement of medical necessity to facilitate the preauthorization submission as set forth in §134.502 of this title (relating to Pharmaceutical Services).

(3) If preauthorization for a drug excluded from the closed formulary is denied, the requestor may submit a request for medical dispute resolution in accordance with §133.308 of this title (relating to MDR by Independent Review Organizations).

(4) In the event of an unreasonable risk of a medical emergency, an interlocutory order may be obtained in accordance with §133.306 of this title (relating to Interlocutory Orders for Medical Benefits) or §134.550 of this title (relating to Medical Interlocutory Order).

(f) Initial pharmaceutical coverage.

(1) Drugs included in the closed formulary which are prescribed for initial pharmaceutical coverage, in accordance with Labor Code §413.0141, may be dispensed without preauthorization and are not subject to retrospective review of medical necessity.

(2) Drugs excluded from the closed formulary which are prescribed for initial pharmaceutical coverage, in accordance with Labor Code §413.0141, may be dispensed without preauthorization and are subject to retrospective review of medical necessity.

(g) Retrospective review. Except as provided in subsection (f)(1) of this section, drugs that do not require preauthorization are subject to retrospective review for medical necessity in accordance with §133.230 of this title (relating to Insurance Carrier Audit of a Medical Bill), §133.240 of this title (relating to Medical Payments and Denials), the Insurance Code, Chapter 1305, applicable provisions of Chapters 10 and 19 of this title.

(1) In order for an insurance carrier to deny payment subject to a retrospective review for pharmaceutical services that fall within the treatment parameters of the certified network's treatment guidelines, the denial must be supported by documentation of evidence-based medicine that outweighs the evidence-basis of the certified network's treatment guidelines.

(2) A prescribing doctor who prescribes pharmaceutical services that exceed, are not recommended, or are not addressed by the certified network's treatment guidelines, is required to provide documentation upon request in accordance with §134.500(13) of this title (relating to Definitions) and §134.502(e) and(f) of this title.

(h)  This section will become effective for all drugs that are prescribed and dispensed for outpatient use on or after MM/DD/YY (intended to be a date certain approximately sixty days after the rule amendment is finally adopted).

The Health Cell - June 20

Learn to Meet High Priority Military Healthcare Needs                                  featuring Jose Salinas, PhD                     The Speaker:   At the US Army Institute of Surgical Research, Dr. Jose Salinas holds leading roles in both research and product development efforts.  In one major project, he and a team approach issues in trauma care with expertise in IT, engineering, and machine learning.  Their goal is to transform time-consuming and subjective manual efforts into data-driven and automated diagnoses and treatments.  With a Ph.D. in Computer Science from Texas A&M University and 20 years of experience in research and project development, Jose is highly regarded for his collaborations with universities and medical device companies to translate research into products for use in the field.   The Story:   Dr. Salinas will share insight into the mission and operations of a unique asset in San Antonio's healthcare and bioscience community: the Army's lead research laboratory dedicated to the care of combat casualties.  You'll learn about the team of military and civilian scientists at Fort Sam Houston who are on the leading edge of innovations in trauma and combat casualty care.  Of particular interest to those with an entrepreneur's mindset will be Jose's discussion about strategies for collaboration with the Institute!                            When Tuesday, June 20, 2017 11:45AM - 1:00PM          Where Hilton San Antonio Airport Hotel 611 NW Loop 410 San Antonio TX 78216                    CLICK HERE TO REGISTER                          UPCOMING Health Cell EVENTS: July 20 - Speaker will be Becky Cap, COO at GenCure and the luncheon will be held at the BioBridge Donor Pavillion from 11:45AM - 1:00PM             August 1 - Speaker will be Kay Scroggins, President & CEO of the Clinical Trials of Texas, Inc. and the luncheon will be held at the Hilton San Antonio Airport Hotel from 11:45AM - 1:00PM              August 24 - This is a special evening event from 5:30PM - 8:00PM and there will be more details to follow                                       Other Upcoming Events: The annual San Antonio Military Health System & Universities Research Forum (SURF) is being held on Friday, June 16 starting at 8:00AM at the UTSA Main Campus.  All area health professionals are invited.  Registration is FREE and there are FREE CME and CNE units available. For more information, click here. Our Mission: Our mission is to leverage San Antonio's collaborative spirit to empower the people who lead the industry.  We do it by bringing people together.  Work in health, biotech, R&D, medicine, military medicine, academia, or services that support them?  We're here for you. Your presence is your pledge. The Health Cell only works when you're here.  So, membership is not based on paying dues, but on being present.  Come to four events in a year, and you're in!  Ask for details at the registration table.  Leading employers make it all happen!   These employers support the careers of leaders in healthcare through their year-round sponsorship of The Health Cell.   Connect with the Health Cell: Website: www.TheHealthCell.org  Email: info@TheHealthCell.org Phone: 210-904-5404